Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 11/20 | 0.59 |
| ▸ | CTSK | P43235 | 9/20 | 0.59 |
| ▸ | CTSB | P07858 | 3/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | BCL2 | P10415 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 3/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28572952 | 1.00 | CTSS (0.59) | CTSSCTSKCTSBCTSLPTPN1 | |
| SCHEMBL30866 | 1.00 | CTSS (0.59) | CTSSCTSKCTSBCTSLPTPN1 | |
| SCHEMBL29373190 | 1.00 | CTSS (0.59) | CTSSCTSKCTSBCTSLPTPN1 | |
| SCHEMBL30865 | 1.00 | CTSS (0.59) | CTSSCTSKCTSBCTSLPTPN1 | |
| SCHEMBL45753 | 1.00 | CTSS (0.59) | CTSSCTSKCTSBCTSLPTPN1 | |
| SCHEMBL30867 | 1.00 | CTSS (0.59) | CTSSCTSKCTSBCTSLPTPN1 | |
| SCHEMBL18765 | 1.00 | CTSS (0.59) | CTSSCTSKCTSBCTSLPTPN1 | |
| SCHEMBL15415630 | 0.93 | ATM (0.57) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL15415629 | 0.93 | ATM (0.57) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL2507124 | 0.93 | ATM (0.57) | CTSSCTSKCTSBCTSLATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118291560-A | Synthesis method of sabatier intermediate (2R, 4S) -5- ([ 1,1' -biphenyl ] -4-yl) -4- ((tert-butoxycarbonyl) amino) -2-methyl ethyl valerate | 江苏德源药业股份有限公司 | 2024-07-05 | — | — | CN | claimed |
| CN-118109529-A | Method for biocatalytically synthesizing Sha Kuba- ([ 1,1' -biphenyl ] -4-yl) -4-amino-2-methyl ethyl valerate serving as Sha Kuba yeast intermediate | 江苏海洋大学 | 2024-05-31 | — | — | CN | claimed |
| CN-118109528-A | Method for biocatalytically synthesizing Sha Kuba- ([ 1,1' -biphenyl ] -4-yl) -4-amino-2-methyl pentanoic acid serving as Sha Kuba yeast intermediate | 江苏海洋大学 | 2024-05-31 | — | — | CN | claimed |
| CN-112745246-A | Purification method of shakubiqu intermediate | 重庆市碚圣医药科技股份有限公司 | 2021-05-04 | — | — | CN | claimed |
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | claimed |
| CN-111265518-A | Composition containing a mixture of biphenyl derivatives and uses thereof | 黄泳华 | 2020-06-12 | — | — | CN | claimed |
| CN-118291560-A | Synthesis method of sabatier intermediate (2R, 4S) -5- ([ 1,1' -biphenyl ] -4-yl) -4- ((tert-butoxycarbonyl) amino) -2-methyl ethyl valerate | 江苏德源药业股份有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118109529-A | Method for biocatalytically synthesizing Sha Kuba- ([ 1,1' -biphenyl ] -4-yl) -4-amino-2-methyl ethyl valerate serving as Sha Kuba yeast intermediate | 江苏海洋大学 | 2024-05-31 | — | — | CN | disclosed |
| CN-118109528-A | Method for biocatalytically synthesizing Sha Kuba- ([ 1,1' -biphenyl ] -4-yl) -4-amino-2-methyl pentanoic acid serving as Sha Kuba yeast intermediate | 江苏海洋大学 | 2024-05-31 | — | — | CN | disclosed |
| US-11370739-B2 | Sacubitril intermediate and preparation method thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-06-28 | — | — | US | disclosed |
| CN-112745246-A | Purification method of shakubiqu intermediate | 重庆市碚圣医药科技股份有限公司 | 2021-05-04 | — | — | CN | disclosed |
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | disclosed |
| CN-108373423-B | Preparation method of Sacubitril-valsartan compound and/or eutectic key intermediate Sacubitril calcium | 成都苑东生物制药股份有限公司 | 2020-10-23 | — | — | CN | disclosed |
| US-8835668-B2 | Process for the preparation of intermediates for the manufacture of NEP inhibitors | NOVARTIS AG (CH) | 2014-09-16 | — | — | US | disclosed |
| US-20130158285-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR THE MANUFACTURE OF NEP INHIBITORS | NOVARTIS AG (CH) | 2013-06-20 | — | — | US | disclosed |
| US-20130158285-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR THE MANUFACTURE OF NEP INHIBITORS | NOVARTIS AG (CH) | 2013-06-20 | — | — | US | disclosed |
| US-20130066101-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | NOVARTIS AG (CH) | 2013-03-14 | — | — | US | disclosed |
| US-20130066101-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | NOVARTIS AG (CH) | 2013-03-14 | — | — | US | disclosed |
| US-20090326066-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO-BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| US-20090326066-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO-BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158285-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR THE MANUFACTURE OF NEP INHIBITORS | MME, ACE, DNPEP | CTSS 507/4885CTSK 983/4885CTSB 348/4885 |
| US-20130066101-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | MME, REN, BCAT2 | CTSS 1512/4885CTSK 3062/4885CTSB 601/4885 |
| US-20090326066-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO-BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | MME, REN, BCAT2 | CTSS 1291/4885CTSK 2982/4885CTSB 521/4885 |
| US-11370739-B2 | Sacubitril intermediate and preparation method thereof | DPP4, ACE, DPP8 | CTSS 378/4885CTSK 146/4885CTSB 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.